Login to Your Account



BiPar Raises $35M Series B For PARP Inhibitor Program

By Trista Morrison


Tuesday, February 27, 2007
With a $35 million Series B financing in hand, BiPar Sciences Inc. expects to generate Phase II data with lead product candidate BSI-201, advance a second compound into the clinic and get a third product through IND filing. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription